Nillion rises 22% following integration of Chainlink’s CCIP
Nillion’s NIL token jumped roughly 22% in 24 hours after the project announced it had integrated Chainlink’s Cross-Chain Interoperability Protocol, known as CCIP. The integration, revealed on August 14, enables secure NIL token transfers between Ethereum and HyperEVM, effectively unlocking trading access on Hyperliquid, one of the most active perpetuals platforms in DeFi.
Chainlink confirmed the integration the same day, giving the announcement an extra layer of credibility that traders clearly appreciated.
What the CCIP integration actually does
For Nillion, this means NIL holders can now move tokens between Ethereum and HyperEVM without relying on less battle-tested bridging solutions. The practical upshot is access to Hyperliquid, which has carved out a reputation as a go-to venue for perpetual futures trading with deep liquidity.
Before this integration, NIL’s trading venues were more limited. Now, traders on Hyperliquid can take positions on the token, which typically drives both volume and price discovery.
Nillion’s bigger strategic picture
Back in March, the project migrated its NIL token from a Cosmos-based chain called nilChain to Ethereum as an ERC-20 token on a 1:1 basis. That migration was a deliberate pivot toward Ethereum’s Layer 2 ecosystem.
Nillion itself operates as what it calls a “blind computer” network. The core idea is privacy-preserving computation, where data can be processed and stored without exposing its contents. The NIL token powers this ecosystem through transaction fees, governance voting, and staking.
Why the market reacted so strongly
Second, the Hyperliquid angle matters more than it might seem at first glance. Perpetuals platforms are where much of crypto’s most active trading volume lives. Getting listed on Hyperliquid doesn’t just add another exchange to the roster. It opens NIL to a class of traders who specialize in leveraged positions and short-term momentum plays.
Third, there’s the timing relative to the Cosmos-to-Ethereum migration. Five months after switching blockchain homes, Nillion is already shipping meaningful integrations that validate the decision.
The elevated trading volume accompanying the price move also suggests this wasn’t just a thin-liquidity spike.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
U.S. non-farm payrolls surge by 165,000 in October, far exceeding expectations! Unemployment rate unexpectedly drops to 4.1%, December rate hike expectations intensify
In October, US non-farm payrolls increased by 165,000, which is 2.5 times the Wall Street median forecast of 65,000 and represents an exceptionally strong deviation of about 5 standard deviations, exceeding the upper limit of all institutional forecast ranges. The unemployment rate unexpectedly fell from 4.2% to 4.1%, while the market had expected it to remain unchanged; average hourly wages also accelerated year-on-year growth to 3.1%. Meanwhile, the previous two months' non-farm payrolls were revised upwards by a total of 84,000. Following the release of the data, the yield on 2-year US Treasury bonds rose by 7 basis points, and the pricing of the probability of a Fed rate hike in December climbed to 70%.
AI Sell-off Hits Anthropic IPO, Potential Valuation Expected to Drop to $1.2–1.3 Trillion
The valuation range discussed by potential investors has been lowered from the previous high of $2 trillion to between $1.2 trillion and $1.3 trillion, and some strategists have even suggested going below $1 trillion to ensure safety. In the face of significant market volatility and financial concerns such as quarterly losses, Anthropic is facing tough decisions, including a discounted valuation, reducing the size of the offering, or postponing the listing.
Moderna Q3 revenue up 29% year-on-year, far exceeding expectations, raises full-year revenue growth guidance to 15%-25% | Earnings Report Insight
Moderna's Q3 revenue increased by 29% year-on-year to $1.31 billion, with profits significantly exceeding expectations. The company raised its 2026 revenue growth guidance to 15%-25%. The ramp-up of next-generation COVID-19 and flu vaccines, along with international market expansion, has driven performance improvement. Phase III data for the personalized cancer vaccine has also shown positive progress. The company is simultaneously advancing cost reduction and pipeline R&D, with year-end cash expectations significantly raised.
Crypto prices
More
